Form F-3 - Registration statement by foreign private issuers:
SEC Accession No. 0001213900-25-125374
Filing Date
2025-12-23
Accepted
2025-12-23 16:37:04
Documents
18

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0270663-f3_enlivex.htm F-3 305293
2 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF THE COMPANY (AS AMENDED THROUGH ea027066301ex4-1_enlivex.htm EX-4.1 163666
3 OPINION OF FISCHER (FBC & CO.) ea027066301ex5-1_enlivex.htm EX-5.1 11719
4 CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING ea027066301ex23-1_enlivex.htm EX-23.1 2537
5 FILING FEE TABLE ea027066301ex-fee_enlivex.htm   iXBRL EX-FILING FEES 13902
6 GRAPHIC image_001.jpg GRAPHIC 5901
7 GRAPHIC ex5-1_001.jpg GRAPHIC 21308
8 GRAPHIC ex23-1_001.jpg GRAPHIC 25211
  Complete submission text file 0001213900-25-125374.txt   693524

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT ea027066301ex-fee_enlivex_htm.xml XML 5070
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV Israel
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV Israel 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-3 | Act: 33 | File No.: 333-292417 | Film No.: 251601191
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)